{"blog": [], "keywords": [{"value": "Medivation Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Pfizer Inc", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/08/23/business/dealbook/medivation-pfizer-14-billion-deal.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}, {"lastname": "PICKER", "firstname": "Leslie", "role": "reported", "organization": "", "rank": 2}], "original": "By ANDREW POLLACK and LESLIE PICKER"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbWide.jpg", "legacy": {"wide": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-articleLarge.jpg", "legacy": {"xlarge": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-articleLarge.jpg", "xlargeheight": "366", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 366}, {"url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1244", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals.", "pub_date": "2016-08-23T04:00:00+0000", "news_desk": "Business", "headline": {"print_headline": "Pfizer Pays $14 Billion to Expand in Oncology", "main": "Pfizer to Buy Cancer Drug Maker in $14 Billion Deal"}, "print_page": "1", "snippet": "The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals....", "_id": "57baea0b95d0e021d7981f10", "slideshow_credits": null, "abstract": "Medivation, maker of prostate cancer medication Xtandi, agrees to $14 billion acquisition bid from Pfizer; deal is part of Pfizer's push into oncology drugs, which appear to be resistant to cost-cutting efforts by insurers; Xtandi sales are expected to reach $4 billion annually. "}